With Porous, Perforated, Apertured, Or Sieved Layer (e.g., Dialyzing Layer, Microporous Layer, Etc.) Patents (Class 424/473)
-
Patent number: 9180045Abstract: A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.Type: GrantFiled: April 7, 2011Date of Patent: November 10, 2015Assignee: Mati Therapeutics Inc.Inventor: Eliot Lazar
-
Patent number: 9149472Abstract: A montelukast composition having a therapeutically effective amount of montelukast in a sustained release is disclosed. A montelukast composition having a therapeutically effective amount of montelukast in an immediate release and sustained release is also disclosed.Type: GrantFiled: November 4, 2013Date of Patent: October 6, 2015Inventor: Jack William Schultz
-
Patent number: 9149460Abstract: The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.Type: GrantFiled: September 27, 2007Date of Patent: October 6, 2015Assignee: Lek Pharmaceuticals d.d.Inventors: Vlasta Humar, Mateja Burjak, Rok Grahek, Mateja Salobir, Janez Kerc, Klemen Kocevar
-
Patent number: 9132096Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.Type: GrantFiled: September 12, 2014Date of Patent: September 15, 2015Assignee: Alkermes Pharma Ireland LimitedInventors: Gurvinder Singh Rekhi, Richard Sidwell
-
Patent number: 9079004Abstract: An access port for providing subcutaneous access to a patient is disclosed. In one embodiment, the port includes an internal body defining a fluid cavity that is accessible via a septum. A compliant outer cover including silicone is disposed about at least a portion of the body. A flange is included with the port body and is covered by the outer cover. The flange radially extends about a perimeter of the port body proximate the septum so as to impede penetration of a needle substantially into the outer cover in instances where the needle misses the septum. The flange can further include both an anchoring feature for securing the outer cover to the port body and an identification feature observable via x-ray imaging technology for conveying information indicative of at least one attribute of the access port. The outer cover provides a suitable surface for application of an antimicrobial/antithrombotic coating.Type: GrantFiled: November 1, 2010Date of Patent: July 14, 2015Assignee: C. R. Bard, Inc.Inventors: Martha Wiley, Jodie L. Noyce, David M. Cise, William R. Barron, Kelly J. Christian, Amir Orome
-
Patent number: 9050391Abstract: The invention relates to an implant, e.g. a stent, bone replacement material, a prosthesis, a scaffold or similar, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterized in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component.Type: GrantFiled: October 17, 2006Date of Patent: June 9, 2015Assignee: NEXILIS AGInventors: Falko Schlottig, Matthias Schnabelrauch, Armin Rex Kautz
-
Patent number: 9028870Abstract: A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.Type: GrantFiled: December 27, 2010Date of Patent: May 12, 2015Assignee: Bend Research, Inc.Inventors: Leah E. Appel, Ronald A. Beyerinck, Mark B. Chidlaw, William J. Curatolo, Dwayne T. Friesen, Kelly L. Smith, Avinash G. Thombre
-
Patent number: 8992962Abstract: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.Type: GrantFiled: May 20, 2013Date of Patent: March 31, 2015Assignee: Intarcia Therapeutics Inc.Inventors: Scott D. Lautenbach, Pedro E. de la Serna, Pauline C. Zamora, Michael A. DesJardin
-
Patent number: 8962019Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: GrantFiled: October 15, 2010Date of Patent: February 24, 2015Assignee: Angelini Pharma, Inc.Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Patent number: 8956654Abstract: An osmotic dosage form which comprising: (a) a core comprising a biologically active ingredient; (b) a semi-permeable membrane covering said core; and (c) at least one passageway through the semi-permeable membrane, wherein the semi-permeable membrane comprises ethyl cellulose, an acrylic or methacrylic polymer and a water-soluble plasticizer with the proviso that the semi-permeable membrane comprises no or not more than 15 weight percent of a water-soluble material excluding any water-soluble plasticizer, based on the total dry weight of the semi-permeable membrane.Type: GrantFiled: June 2, 2009Date of Patent: February 17, 2015Assignee: Dow Global Technologies LLCInventors: Yong Gan, Chunliu Zhu, Sophie Zhai, Robert I. Schmitt, Ka Chun A. Chan
-
Patent number: 8936810Abstract: Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer or to one or another interface of two formulation layers depending on the formulation orientation of the tablet.Type: GrantFiled: October 18, 2012Date of Patent: January 20, 2015Assignee: ALZA CorporationInventors: Steven F. Stone, Johan H. Geerke
-
Patent number: 8920835Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.Type: GrantFiled: November 22, 2010Date of Patent: December 30, 2014Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, QILU Pharamceutical Co., Ltd.Inventors: Yong Gan, Chunliu Zhu, Qingmin Yang, Jingyi Wang, Xiaoqing Zheng, Li Gan, Xinxin Zhang
-
Publication number: 20140335178Abstract: The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form.Type: ApplicationFiled: May 19, 2014Publication date: November 13, 2014Applicants: BRISTOL-MYERS SQUIBB COMPANY, PFIZER INC.Inventor: Richard G. Nause
-
Publication number: 20140302141Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: ApplicationFiled: February 24, 2014Publication date: October 9, 2014Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: FERNANDO G. TONEGUZZO, GLENN A. MEYER, Marcelo A. RICCI, Marcelo A. COPPARI, ANA C. PASTINI, GUSTAVO A. FISCHBEIN
-
Publication number: 20140271842Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Pfizer Inc.Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock
-
Patent number: 8792071Abstract: A cellulose acylate film containing a cellulose acylate having a total degree of substitution of from 1.5 to 2.6 and a polycondensate ester, satisfying 3.4?Rth(550)/d, 40 nm?Re(550)?60 nm and 100 nm?Rth(550)?300 nm, having a film thickness of from 20 to 45 ?m and having an internal haze of from 0.005 to 0.07% (d means the film thickness (?m)).Type: GrantFiled: March 28, 2012Date of Patent: July 29, 2014Assignee: Fujifilm CorporationInventors: Hirofumi Toyama, Jun Takeda, Yoshiaki Hisakado, Yoji Ito
-
Patent number: 8747897Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent.Type: GrantFiled: April 27, 2006Date of Patent: June 10, 2014Assignee: Supernus Pharmaceuticals, Inc.Inventors: Argaw Kidane, Padmanabh P. Bhatt
-
Patent number: 8733368Abstract: A device which facilitates the absorption of nicotine in order to reduce the incidence of tobacco smoking is disclosed. The device includes a tube defining an interior space. The tube has a first end with an opening and a second end. An inhalable, flowable liquid or gel composition is disposed in the interior space of the tube. The composition may include water, at least one vitamin, a flavoring agent, and nicotine. The flavoring agent may include an intense sweetener such as sucralose, and a natural or artificial fruit flavor. A user inhales on the first end of the tube of the device as a substitute oral activity to tobacco smoking and thereby ingests a source of nicotine that reduces the withdrawal symptoms experienced when smoking is stopped.Type: GrantFiled: July 16, 2010Date of Patent: May 27, 2014Assignee: Smoke-Break, Inc.Inventors: Brett J. Roth, Terrill S. Clayton
-
Patent number: 8703193Abstract: The present invention relates to controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof. The controlled porosity osmotic pump tablets do not need to be drilled by laser, but provides controlled porosity for drug release by adding a suitable quantity of pore-forming agents into the semipermeable membrane. In specific embodiments, the present invention relates to controlled porous osmotic pump tablets comprising venlafaxine or metoprolol or pharmaceutically acceptable salts thereof.Type: GrantFiled: October 16, 2007Date of Patent: April 22, 2014Assignee: Cosci Med-Tech Co. Ltd.Inventors: Jingang Wang, Haisong Jiang
-
Patent number: 8685451Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: GrantFiled: June 18, 2008Date of Patent: April 1, 2014Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
-
Patent number: 8684739Abstract: Provided is a slow-release delivery vehicle for delivering at least one active ingredient into a film coating, comprising a population of stable, homogeneously-dispersed, porous polymeric or co-polymeric beads having a network of pores, wherein the at least one active ingredient is held within the bead particles and within the network of pores and slowly released by internal flow, and wherein the network of pores is substantially non-collapsible upon removal of the active ingredient. The porous co-polymer bead preparation comprises a continuous aqueous phase solution containing a monomeric mixture of at least one polyvinylaromatic monomer and at least one porogen forming a network that comprising (i) macropores; (ii) mesopores; (iii) micropores; and (iv) gel porosity. Also provided are methods of preparing the porous co-polymer bead preparation; and for its use as a slow-release delivery vehicle.Type: GrantFiled: March 14, 2003Date of Patent: April 1, 2014Assignee: Mycone Dental Supply Co., Inc.Inventors: Larry W. Steffier, David Kurz, Robert R. Raney, Cary B. Robinson
-
Patent number: 8668930Abstract: Provided is a slow-release delivery vehicle for delivering at least one active ingredient into a film coating, comprising a population of stable, homogeneously-dispersed, porous polymeric or co-polymeric beads having a network of pores, wherein the at least one active ingredient is held within the bead particles and within the network of pores and slowly released by internal flow, and wherein the network of pores is substantially non-collapsible upon removal of the active ingredient. The porous co-polymer bead preparation comprises a continuous aqueous phase solution containing a monomeric mixture of at least one polyvinylaromatic monomer and at least one porogen forming a network that comprising (i) macropores; (ii) mesopores; (iii) micropores; and (iv) gel porosity. Also provided are methods of preparing the porous co-polymer bead preparation; and for its use as a slow-release delivery vehicle.Type: GrantFiled: March 29, 2006Date of Patent: March 11, 2014Assignee: Mycone Dental Supply Co., Ltd.Inventors: Larry Steffier, David Kurz, Robert B. Raney, Cary B. Robinson
-
Patent number: 8668931Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.Type: GrantFiled: May 8, 2013Date of Patent: March 11, 2014Assignee: Actavis, Inc.Inventors: Unchalee Kositprapa, Robert I. Goldfarb, John R. Cardinal, Avinash Nangia
-
Patent number: 8662087Abstract: A device which facilitates the absorption of nicotine in order to reduce the incidence of tobacco smoking is disclosed. The device includes a tube defining an interior space. The tube has a first end with an opening and a second end. An inhalable, flowable liquid or gel composition is disposed in the interior space of the tube. The composition may include water, at least one vitamin, a flavoring agent, and nicotine. The flavoring agent may include an intense sweetener such as sucralose, and a natural or artificial fruit flavor. A user inhales on the first end of the tube of the device as a substitute oral activity to tobacco smoking and thereby ingests a source of nicotine that reduces the withdrawal symptoms experienced when smoking is stopped.Type: GrantFiled: January 5, 2012Date of Patent: March 4, 2014Assignee: Smoke-Break, Inc.Inventors: Brett J. Roth, Terrill S. Clayton
-
Publication number: 20140030330Abstract: The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form.Type: ApplicationFiled: July 2, 2013Publication date: January 30, 2014Inventor: Richard G. Nause
-
Patent number: 8637080Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: GrantFiled: June 25, 2008Date of Patent: January 28, 2014Assignee: Osmotica Kereskedelmi és Szolgáltató, KFTInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Patent number: 8591947Abstract: A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.Type: GrantFiled: September 24, 2012Date of Patent: November 26, 2013Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Juan A. Vergez, Marcelo A. Ricci
-
Patent number: 8580303Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: April 1, 2013Date of Patent: November 12, 2013Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou
-
Patent number: 8574626Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.Type: GrantFiled: July 18, 2012Date of Patent: November 5, 2013Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Juan A. Vergez, Joaquina Faour, Ana C. Pastini, Guido S. Bigatti, Glenn A. Meyer, Ethel C. Feleder, Marcelo A. Ricci, Marcelo A. Coppari, Marcelo F. Befumo
-
Publication number: 20130287850Abstract: Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be employed to produce pharmaceutical compositions, such as controlled release dosage forms, adjusted to a specific administration scheme.Type: ApplicationFiled: June 26, 2013Publication date: October 31, 2013Inventors: Christine Andersen, Karsten Lindhardt, Jan Martin Oevergaard, Louise Inoka Lyhne-Iversen, Martin Rex Olsen, Anne-Mette Haahr, Pernille Kristine Hoeyrup Hemmingsen
-
Publication number: 20130287849Abstract: Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be employed to produce pharmaceutical compositions, such as controlled release dosage forms, adjusted to a specific administration scheme.Type: ApplicationFiled: June 26, 2013Publication date: October 31, 2013Inventors: Christine Andersen, Karsten Lindhardt, Jan Martin Oevergaard, Louise Inoka Lyhne-Iversen, Martin Rex Olsen, Anne-Mette Haahr, Pernille Kristine Hoeyrup Hemmingsen
-
Publication number: 20130259941Abstract: Dosage forms having a core having a surface having means for controlling release(s) on an active agent(s); methods of manufacturing, tools used in manufacturing; and uses of the dosage forms are described.Type: ApplicationFiled: December 12, 2011Publication date: October 3, 2013Applicant: PURDUE PHARMA L.P.Inventor: Edward O'Donnell
-
Patent number: 8535701Abstract: The invention is directed to a device for delivering an active agent formulation for a predetermined administration period. An impermeable reservoir is divided into a water-swellable agent chamber and an active agent formulation chamber. Fluid from the environment is imbibed through a semipermeable plug into the water-swellable agent chamber and the active agent formulation is released through a back-diffusion regulating outlet. Delivery periods of up to 2 years are achieved.Type: GrantFiled: October 4, 2012Date of Patent: September 17, 2013Assignee: Intarcia Therapeutics, Inc.Inventors: John R. Peery, Keith E. Dionne, Felix A. Landrau, Bonnie J. Eckenhoff, Scott D. Lautenbach, Judy A. Magruder, Jeremy C. Wright
-
Publication number: 20130209562Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: ApplicationFiled: March 13, 2013Publication date: August 15, 2013Applicant: ALZA CORPORATIONInventor: ALZA CORPORATION
-
Patent number: 8470368Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.Type: GrantFiled: June 2, 2011Date of Patent: June 25, 2013Assignee: Watson Pharmaceuticals, Inc.Inventors: Unchalee Kositprapa, Robert I. Goldfarb, John R. Cardinal, Avinash Nangia
-
Patent number: 8470353Abstract: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.Type: GrantFiled: January 12, 2013Date of Patent: June 25, 2013Assignee: Intarcia Therapeutics, Inc.Inventors: Scott D. Lautenbach, Pedro E. de la Serna, Pauline C. Zamora, Michael A. DesJardin
-
Patent number: 8409613Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: February 14, 2012Date of Patent: April 2, 2013Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Patent number: 8394409Abstract: A controlled extended drug release technology for the controlled extended release of hydrophobic or hydrophilic drugs or therapeutically active agents consisting of a homogeneous blend of one or more therapeutic agents, gas generators and surrounded by one or more layers of coat made of thermoplastic water insoluble cellulose derivatives, acrylic polymers, superdisintegrants and optionally an oil, antioxidants and electrolytes. The technology platform is capable of releasing therapeutic agents via zero, first or pseudo first order release.Type: GrantFiled: July 1, 2004Date of Patent: March 12, 2013Assignee: Intellipharmaceutics Corp.Inventors: Isa Odidi, Amina Odidi
-
Patent number: 8367095Abstract: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.Type: GrantFiled: August 31, 2012Date of Patent: February 5, 2013Assignee: Intarcia Therapeutics, Inc.Inventors: Scott D. Lautenbach, Pedro E. de la Serna, Pauline C. Zamora, Michael A. DesJardin
-
Patent number: 8333992Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: July 27, 2012Date of Patent: December 18, 2012Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Patent number: 8333991Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: July 19, 2012Date of Patent: December 18, 2012Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Patent number: 8329217Abstract: A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.Type: GrantFiled: February 15, 2006Date of Patent: December 11, 2012Assignee: Osmotica Kereskedelmi es Szolgaltato KftInventors: Juan A. Vergez, Marcelo A. Ricci
-
Patent number: 8323691Abstract: Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer or to one or another interface of two formulation layers depending on the formulation orientation of the tablet.Type: GrantFiled: March 11, 2009Date of Patent: December 4, 2012Assignee: Alza CorporationInventors: Johan H. Geerke, Steven F. Stone
-
Publication number: 20120301547Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.Type: ApplicationFiled: November 22, 2010Publication date: November 29, 2012Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, QILU PHARMACEUTICAL CO., LTD.Inventors: Yong Gan, Chunliu Zhu, Qingmin Yang, Jingyi Wang, Xiaoqing Zheng, Li Gan, Xinxin Zhang
-
Patent number: 8298581Abstract: A controlled release pharmaceutical composition for oral use is provided in the form of a coated matrix composition, the matrix composition comprising i) a mixture of a first and a second polymer that have plasticizing properties and which have melting points or melting intervals of a temperature of at the most 200° C.Type: GrantFiled: March 26, 2004Date of Patent: October 30, 2012Assignee: Egalet A/SInventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Anne-Marie Lademann
-
Patent number: 8293799Abstract: The osmotic devices of the present invention include a single core comprising a salt of a drug and an osmotic salt, wherein the drug salt and the osmotic salt have a common ion. The release rate of the active drug is reduced, and the release profile of the active drug is modified, from a first order release profile to a zero order, pseudo-zero order, or sigmoidal release profile, by increasing the amount of the sodium chloride in the core of the device. In one embodiment the sodium chloride is used to modify a controlled release profile to a delayed and controlled release profile.Type: GrantFiled: December 13, 2004Date of Patent: October 23, 2012Assignee: Osmotica Keresleedelmo és Szolgáltató KFTInventors: Ethel C. Feleder, Glenn A. Meyer, Marcelo A. Ricci, Joaquina Faour, Ana C. Pastini, Marcelo F. Befumo
-
Patent number: 8273365Abstract: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.Type: GrantFiled: March 29, 2012Date of Patent: September 25, 2012Assignee: Intarcia Therapeutics, Inc.Inventors: Scott D. Lautenbach, Pedro E. de la Serna, Pauline C. Zamora, Michael A. DesJardin
-
Patent number: 8252332Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: March 29, 2010Date of Patent: August 28, 2012Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Patent number: 8252331Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt.Type: GrantFiled: November 28, 2005Date of Patent: August 28, 2012Assignee: Osmotica Kereskedelmi és Szolgáltató, KFTInventors: Glenn A. Meyer, Ethel C. Feleder, Marcelo A. Ricci, Marcelo A. Coppari, Marcelo F. Befumo, Joaquina Faour, Juan A. Vergez
-
Patent number: RE44459Abstract: The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.Type: GrantFiled: March 2, 2012Date of Patent: August 27, 2013Assignee: Alza CorporationInventors: Anthony L. Kuczynski, Atul Devdatt Ayer, Patrick S. L. Wong